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Abstract
The World Health Organization (WHO) guidelines on antiretroviral therapy (ART) deﬁne treatment failure as 2 consecutive viral loads
(VLs) ≥1000copies/mL. There is, however, little evidence supporting 1000 copies as an optimal threshold to deﬁne treatment failure.
Objective of this study was to assess the correlation of the WHO deﬁnition with the presence of drug-resistance mutations in patients
who present with 2 consecutive unsuppressed VL in a resource-limited setting.
In 10 nurse-led clinics in rural Lesotho children and adults on ﬁrst-line ART for ≥6 months received a ﬁrst routine VL. Those with
plasma VL ≥80copies/mL were enrolled in a prospective study, receiving enhanced adherence counseling (EAC) and a follow-up VL
after 3 months. After a second unsuppressed VL genotypic resistance testing was performed. Viruses with major mutations against
≥2 drugs of the current regimen were classiﬁed as “resistant”.
A total of 1563 adults and 191 children received a ﬁrst routine VL. Of the 138 adults and 53 children with unsuppressed VL (≥80
copies/mL), 165 (116 adults; 49 children) had a follow-up VL after EAC; 108 (74 adults; 34 children) remained unsuppressed and
resistance testing was successful. Ninety of them fulﬁlled the WHO deﬁnition of treatment failure (both VL ≥1000copies/mL); for
another 18 both VL were unsuppressed but with<1000copies/mL. The positive predictive value (PPV) for the WHO failure deﬁnition
was 81.1% (73/90) for the presence of resistant virus. Among the 18 with VL levels between 80 and 1000copies/mL, thereby
classiﬁed as “non-failures”, 17 (94.4%) harbored resistant viruses. Lowering the VL threshold from 1000copies/mL to 80copies/mL
at both determinations had no negative inﬂuence on the PPV (83.3%; 90/108).
The current WHO-deﬁnition misclassiﬁes patients who harbor resistant virus at VL below 1000c/mL as “nonfailing.” Lowering the
threshold to VL ≥80copies/mL identiﬁes a signiﬁcantly higher number of patients with treatment-resistant virus and should be
considered.
Abbreviations: ART = antiretroviral therapy, c/mL = copies/mL, DBS = dried blood spot, EAC = enhanced adherence
counseling, HIV = human immunodeﬁciency virus, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside
reverse transcriptase inhibitor, VL = viral load, WHO = World Health Organization.
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1. Introduction 2.2. Study setting
2.3. Participants and study procedure
Labhardt et al. Medicine (2016) 95:28 MedicineThe 2013 Consolidated Guidelines of the World Health
Organization (WHO) “On the Use of Antiretroviral Drugs for
Treating and Preventing HIV Infection” introduced routine viral
load (VL) monitoring of patients on antiretroviral therapy (ART)
in resource-limited settings.[1] For VLs ≥1000copies/mL (c/mL)
the WHO recommends adherence support for the following 3 to
6 months and then a conﬁrmatory VL. If the follow-up VL
remains ≥1000c/mL despite good adherence, the patient is to be
empirically switched to a second-line regimen. In contrast,
patients with VLs below <1000c/mL should be continued with
unchanged ﬁrst-line ART.[1]
Only in 2013, theWHO had adjusted the level from previously
5000 to 1000c/mL, although an “optimal threshold” for deﬁning
treatment failure had never been scientiﬁcally deﬁned; the WHO
rationale for the 1000 copies reads: “clinical and epidemiological
studies show that the risk of human immunodeﬁciency virus
(HIV) transmission and disease progression is very low when
the VL is lower than 1000c/mL.”[1] Another important
rationale for a threshold at 1000c/mL is that many programs
in remote rural areas rely on dry blood spot (DBS) specimens.
DBS does not reliably detect viremias below 1000c/mL. Thus
the recommendation to use 1000c/mL for deﬁning treatment
failure is maintained in the revised 2015 version of the WHO
guidelines.[2]
In contrast, various recent studies from high-income countries
revealed that a high proportion of patients on ART with
unsuppressed VL far below 1000c/mL already harbor mutations
known to confer resistance to the current ART regimen that
will ultimately lead to treatment failure.[3–5] Consequently
US- and European guidelines today recommend thresholds
below 1000c/mL for second line switching.[6,7] To our
knowledge, there are currently no studies from resource-limited
settings assessing if the WHO-proposed threshold for failure
discriminating “true failure,” deﬁned as presence of relevant
drug-resistance mutations, from “non-failure” without relevant
virus mutations.
This registered prospective study assessed the correlation of
the WHO deﬁnition of virologic failure with the presence or
absence of critical drug-resistance mutations. The study was
conducted in 10 rural nurse-led clinics in rural Lesotho, Southern
Africa.2. Materials and methods
2.4. Outcome measures2.1. Study design
The study entitled “Comorbidities and Virologic Outcome
Among Patients on Antiretroviral Therapy in Rural Lesotho”
(CART-1 study) is a registered prospective observational study
assessing comorbidities and virologic outcomes among patients
on ﬁrst-line ART in 10 rural facilities in Lesotho (www.
clinicaltrials.gov; ID: NCT02126696). This study has 2 parts:
ﬁrst, a cross-sectional assessment of routine VL among patients
on ﬁrst-line ART and, thereafter, a cohort study involving those
patients with unsuppressed VL during part 1. One of the 2
predeﬁned primary outcomes of the CART-1 study was to assess
the WHO VL algorithm in a typical resource-limited setting with
sensitive plasma VL. Using genotypic resistance testing, we
probed the suitability of the WHO failure deﬁnition for
predicting the presence of major drug-resistance mutations
against the current ﬁrst-line regimen.2The study was conducted during the year 2014 in 2 districts of
Lesotho, Thaba-Tseka and Butha-Buthe, each including 1
hospital and 4 health centers, where HIV care is exclusively
provided by trained nurses. All sites receive support through
SolidarMed, a Swiss not-for-proﬁt organization that is assisting
the Ministry of Health in the rollout of ART in Lesotho since
2005. The setting has been described previously.[8]
In 2013, Lesotho had revised its own national ART guidelines,
adopting the WHO recommendation of routine VL monitoring,
which suggests for VL ≥1000c/mL to strengthen and monitor
adherence over a period of 3 to 6 months, followed by a second
VL. A VL ≥1000c/mL at follow-up triggers the switch to second-
line ART. With VL below that level patients stay on ﬁrst-line
ART.[1,2,9] During the conduct of the study, VL monitoring
and genotypic resistance testing were unavailable for patients in
routine HIV care.Participants were recruited between May and June 2014 for the
cross-sectional study of part 1, which assessed virologic outcomes
and comorbidities among patients attending routine ART care at
the 10 study facilities. Eligibility criterion was prior continuous
ﬁrst-line ART for ≥6 months. Exclusion criteria were shorter
periods on ART, documented treatment interruption of ≥7
consecutive days during the last 3 months, or being on a second-
line regimen. Outcomes of part 1 in adults and children have been
reported elsewhere.[10,11] Based on the speciﬁcations of our
validated test system, pediatric and adult patients with VL above
80c/mL during part 1 were deﬁned as “unsuppressed.”
Part 2 of the study was limited to patients with unsuppressed
VL in part 1: Following the WHO guidelines, these patients
received enhanced adherence counseling (EAC) and follow-up
VL after 3 months. But, deviating from the WHO guidelines, all
patients with any detectable VL, even below 1000 copies,
received EAC and follow-up VL.
A health professional informed the patients about an unsup-
pressed VL and organized a follow-up for EAC. Adherence
interventions included at least 1 of the following: focus-group
discussion among patients with unsuppressed VL, one-to-one
adherence counseling with nurse or lay-counselor, or directly
observed therapy in the community. A follow-up VL was
obtained 3 months after ﬁrst EAC (October to November 2014),
and viral genotyping was performed on the follow-up VL sample
if VL remained unsuppressed with at least 80c/mL.Primary outcome of this analysis was the predictiveness of the
WHO deﬁnition of virologic treatment failure with repeated VL
elevation to ≥1000c/mL for detecting therapy-relevant viral
resistance mutations. Following the current WHO recommenda-
tion only patients with ﬁrst and follow-up VL ≥1000c/mL were
labeled “failures,” whereas patients with any unsuppressed level
below 1000c/mL continued to be considered “non-failures”. The
prevalence of critical viral resistance mutations was assessed in
both groups for all samples with successful HIV ampliﬁcation.
Resistance against the ﬁrst-line regimen was deﬁned by the
presence of at least “low-level resistance” against at least 2 of the
3 drugs in a patient’s current regimen according to StanfordDrug
Resistance Database version 7.0.
A secondary outcome described the frequencies of resistance analysis was collected in plasma preparation tubes (PPTs),
Labhardt et al. Medicine (2016) 95:28 www.md-journal.commutations against nucleosidic (NRTI) and nonnucleoside reverse
transcriptase inhibitors (NNRTI) among patients with sustained
VL above 80c/mL.2.5. Data collection
2.6. Statistical analysisPatients’ baseline characteristics were recorded when blood for
the ﬁrst VL measurement was drawn. Trained, supervised lay-
counselors interviewedparticipantsusing a structuredquestionnaire
on social and demographic characteristics and adherence. Adher-
ence was assessed using pill-count and self-reported adherence on a
visual analog scale. Following the interview, participants had their
regular ART visits with clinical assessment and review of medical
and therapeutic history. Questionnaires were digitalized in Lesotho
and subsequently processed with Data-Scan 5.7.7 (Neoptec,
Montpellier, France) for electronic data capture. Prior to analysis,
all data were manually cross-checked against the original records.
Routine laboratory exams (full blood count, CD4-cell count,
transaminases, serum creatinine) were performed at the certiﬁed
national laboratories of the 2 study hospitals. Blood for virologic1‘563 paents
1‘425 (91.2%) VL <80 c/mL
1‘811 adult paents ass
1‘598 paen
23 (82.1%) receive 2nd VL
19 (82.6%) 2nd VL <80 c/mL
2 (8.7%) 
VL 80-999 c/mL
2 (8.7%) 
VL ≥1000 c/mL
1 (3.6%) death (not-AIDS-related)
4 (14.3%) Lost to follow-up
28 (20.3%) VL 80-999 c/mL
138 (8.8%) V
Figure 1A. Enrolment and follow-up of adult study participants.
3centrifuged within 8hours and stored frozen at 80°C. Within
3 weeks of storage, PPTs were then shipped on dry ice to a
reference laboratory in Switzerland. Samples were thawed
without agitation, and viral RNA extraction was performed
from the top 1mL plasma fraction using NucliSENS easyMag
(bioMérieux, Geneva, CH). VL determination was performed
with a sensitive in-house protocol with a quantiﬁcation limit at
below 80c/mL, targeting the viral LTR[12] and validated against
the commercial diagnostic protocol COBAS TaqMan HIV-1 test,
v2.0. For genotypic resistance testing we used material retained
after NucliSENS easyMag extraction of the clinical specimen for
the second VL measurement. Wherever sequencing was not
successful, the sample of the ﬁrst VL was used. (Five of the 108
determinations had to be repeated on the ﬁrst VL sample.)The study sample size was chosen to estimate the prevalence of
unsuppressed VL during the cross-sectional part 1 of this study:
we assumed that among the adults about 15% would have anreceive 1st VL
essed for enrollment
213 excluded:
- 138 on ART < 6 months
- 50 refuse to parcipate
- 25 on second-line ART
ts enrolled
35 missing data:
- 26 missing VL-sample
- 9 missing quesonnaires
93 (84.5%) receive 2nd VL
64 (68.8%)
VL ≥1000 c/mL
12 (12.9%) 
VL 80-999 c/mL
17 (18.3%) 2nd VL <80 c/mL
3 (2.7%) died (AIDS-related)
5 (4.6%) switched aer 1st VL
9 (8.2%) lost to follow-up 
110 (79.7%) VL ≥1000 c/mL
L≥80 c/mL
unsuppressed VL. To achieve a precision of 2%, a minimum “Ethikkomission Nordwest- und Zentralschweiz” (EKNZ) in
3. Results
191 children included in analysis
138 (72.3%) VL <80 c/mL
7 (13.2%) VL 80-999 c/mL 46 (86.8%) VL ≥1000 c/mL
7 receive 2nd VL 42 receive 2nd VL
30 (71%)
VL ≥1000 c/mL
5 (71%) VL <80 c/mL
2 (29%) 
VL 80-999 c/mL
4 (10%) 
VL 80-999 c/mL
8 (19%) VL <80 c/mL
0 (0%) 
VL ≥1000 c/mL
3 (6.5%) lost to follow-up
1 (2.2%) died
240 pediatric paents assessed for enrollment
196 children enrolled
44 excluded:
- 28 no caregiver for consent
- 11 on ART <6 months
- 5 on second-line ART
5 excluded
53 (27.7%) VL≥ 80c/mL
- 5 excluded 
- 5 missing VL-informaon
Figure 1B. Enrolment and follow-up of pediatric study participants.
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4sample size of 1225 individuals was needed. Due to much lower
numbers of children on ART in the study facilities, convenience
sampling was applied for children. Unless speciﬁed otherwise, all
quantitative variables are given in median and interquartile
ranges (IQR). Exact binomial quantiles were used to compute the
conﬁdence intervals of proportions. Data from children (<16
years) and adults were analyzed separately. Calculations of
sensitivity and speciﬁcity at VL ≥1000 and VL ≥80c/mL were
based on the assumption that all study participants with
suppressed VL (<80c/mL) would not harbor resistant HIV
and could thus be categorized as true negatives in the four-by-
four table. All analyses were run on R 2.15.3 (the R Foundation
for Statistical Computing), and TIBCO Spotﬁre S+ 8.1 for
Windows (TIBCO Software Inc., Munich, GER).
2.7. Ethical considerations
Ethics approval was received by the National Health Research
and Ethics Committee of Lesotho (ID 01-2014) and theSwitzerland (ID 2014-029). Prior to enrolment patients provided
individual oral and written informed consent. For children aged
<16 years, a main caregiver had to provide oral and written
informed consent.
2.8. Role of the funding source
The Swiss Foundation for Talent and Excellence on Biomedical
Research, funder of this study, was not involved in design,
implementation, and publication of the study.3.1. Enrolment of adult participants
The enrolment scheme of adult patients is displayed in Fig. 1A: A
total of 1811 adult patients attended ART consultations during
the recruitment period, 213 (11.8%) were excluded based on the
prespeciﬁed exclusion criteria and 35 (1.9%) due to missing data.
Out of 1563 patients analyzed, 1425 (91.2%) had VL below the 3.2. Enrolment of pediatric participants
Table 1
Baseline characteristics of the 138 adult patients with unsup-
pressed VL (≥80c/mL) who were enrolled in the cohort study.
Parameters
Clinical characteristics
Median age (IQR) 41.1 (32.4–49.9)
Female gender (%) 65.9
Median CD4-cell count (cells/mL) (IQR) 351 (182–520)
Median hemoglobin (g/dL) (IQR) 13.4 (12.2–14.3)
Median BMI (kg/m2) 22.2 (20.2–25.8)
Clinical failure (new WHO 3 or 4 condition) 10 (7.4%)
Type of facility
Health center 77 (55.8%)
District hospital 61 (44.2%)
Median time on ART (y) (IQR) 4.1 (2.4–5.7)
First-line regimen’s NRTI backbone
Zidovudine/lamivudine 70 (50.7%)
Tenofovir/lamivudine 67 (48.6%)
Abacavir/lamivudine 1 (0.7%)
First-line regimen’s NNRTI
Efavirenz 90 (65.2%)
Nevirapine 48 (34.8%)
History of NRTI substitution 34 (24.6%)
Sociodemographic characteristics
Median travel time to clinic (min) (IQR) 70 (60–150)
Mode of travel
Walking 96 (72.2%)
Taxi 28 (21.1%)
Donkey/horse 4 (3.0%)
Other 5 (3.8%)
Educational level
No completed primary education 74 (54.0%)
Completed primary education 36 (26.3%)
Secondary education and higher 27 (19.7%)
Civil status
Single 14 (10.3%)
Concubinary 4 (2.9%)
Widowed 38 (27.9%)
Married 80 (58.88%)
Employment status
Employed 17 (12.6%)
Self-employed 31 (23.0%)
Unemployed 87 (64.4%)
BMI = body-mass index, IQR = interquartile range, NNRTI = nonnucleoside reverse transcriptase
inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, WHO = World Health Organization.
Table 2
Baseline characteristics of the 53 pediatric patients with unsup-
pressed VL who were enrolled in the cohort study.
Parameter
Clinical characteristics
Median age at study visit (IQR) 9.7 (5.6 to 13.0)
Median age at ART start (IQR) 5.1 (1.6 to 8.5)
Female gender (%) 47.2
Median CD4 count if age ≥5 years (IQR), n=41 690 (432 to 1015)
Median CD4 percentage if age <5 years, n=12 22% (17% to 32%)
Median hemoglobin (g/dL) (IQR) 12.8 (12.0 to 15.3)
Clinical failure at study visit (new WHO 3 or 4 condition) 2 (3.8%)
Median height for age Z-score (HAZ) at study visit 2.5 (3.5 to 1.3)
HAZ ≥2 at study visit 21 (40.4%)
HAZ <2 at study visit 31 (59.6%)
Missing information 1
Treatment history
Type of facility
Health center 21 (39.6%)
District hospital 32 (60.4%)
Median time on ART (IQR) 3.7 (2.1–4.8)
First-line regimen’s NRTI backbone
Zidovudine/lamivudine 47 (88.7%)
Tenofovir/lamivudine 2 (3.8%)
Abacavir/lamivudine 4 (7.5%)
First-line regimen’s NNRTI/PI
EFV 14 (26.4%)
NVP 36 (67.9%)
Lopinavir-based ﬁrst line 3 (5.7%)
History of NRTI substitution 13 (24.5%)
Sociodemographic characteristics
Median travel time to clinic (min) 60 (30 to 105)
Mode of travel
Walking 32 (60.4%)
Taxi 21 (39.6%)
Donkey/horse 0
Other 0
Orphanhood
Both parents alive 27 (50.9%)
One parent alive 14 (26.4%)
No parent alive 11 (20.8%)
BMI = body-mass index, IQR = interquartile range, NNRTI = nonnucleoside reverse transcriptase
inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, VL = viral load,
WHO = World Health Organization.
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5detection limit of 80c/mL, 138 had unsuppressed VL (28 (1.8%)
VL 80–999c/mL; 110 (7.0%) VL ≥1000c/mL). Table 1
summarizes the characteristics of the 138 adult patients with
unsuppressed VL. They all received information about their on-
going viremia within amedian of 28 days (IQR: 22–31 days) after
blood draw. Based on the clinical assessment by the study
physician, 5 were clinically unstable and were switched without
awaiting a follow-up VL.
Of the 133 patients with unsuppressed VL, 116 (87.2%) had a
documented follow-up VL after EAC, and 22 failed to have a
follow-up VL for the reasons summarized in Fig. 1A. The median
time between ﬁrst and follow-up VLwas 107 days (IQR 97–121).
Of the 116 adults with available follow-up VL-result, 36 (31.0%)
achieved resuppression to<80c/mL, 14 (12.1%) had a follow-up
VL 80 to 999c/mL, and 66 (56.9%) a VL ≥1000c/mL (Fig. 1A).
There was no signiﬁcant association between participants’
clinical and sociodemographic characteristics (Table 1) and viral
resuppression at follow-up VL.Figure 1B details the pediatric cohort: out of a total of 240
children 44 (18.8%) were excluded due to prespeciﬁed exclusion
criteria or missing data (5; 1.7%). Among the analyzed 191
pediatric patients for 138 (72.3%), the VL was below the
detection limit, 7 (3.6%) had a VL of 80 to 999c/mL, and 46
(24.1%) ≥1000c/mL. Table 2 summarizes the characteristics of
the 53 children with a detectable ﬁrst VL. Caregivers of the 53
children received information about the unsuppressed VL within
a median of 25 days (IQR 23–32 days) after blood draw, and 49
(92.5%) received EAC, and their children had a documented
follow-up VL (Fig. 1B). Median time between ﬁrst and second VL
was 99 days (IQR 93–109 days). Of the 49 children with an
unsuppressed ﬁrst and a follow-up VL determination, 13
(26.5%) achieved resuppression to <80c/mL, 6 (12.2%) had
80 to 999c/mL, and the remaining 30 children a VL ≥1000c/mL
(Fig. 1B). There was no signiﬁcant association between the
participants’ clinical and sociodemographic characteristics
(Table 2) and viral resuppression at follow-up VL.
3.3. WHO-deﬁned failure and viral resistance investigating the VL threshold of 1000c/mL for the presence or
Table 3
Virologic failure according to WHO deﬁnition and prevalence of at least “low-level drug resistance” against at least 2 drugs of the current
ﬁrst-line regimen in children and adults.
N DRM against ≥2 drugs of ﬁrst line DRM against <2 drugs of ﬁrst line
Adult patients 74 66 8
Failures (ﬁrst and follow-up VL ≥1000c/mL) 61 53 (87%) 8 (13%)
Non-failures (ﬁrst and/or follow-up VL 80–999c/mL) 13 13 (100%) 0 (0%)
Pediatric patients 34 24 10
Failures (ﬁrst and follow-up VL ≥1000c/mL) 29 20 (69%) 9 (31%)
Non-failures (ﬁrst and/or follow-up VL 80–999c/mL) 5 4 (80%) 1 (20%)
DRM = drug-resistance mutation, VL = viral load.
Labhardt et al. Medicine (2016) 95:28 MedicineGenotyping was successful in 108 (93.1%) of the 116 patients
with unsuppressed follow-up VL (74/80 adults; 34/36 children).
For the remaining 8 samples no RT-PCR product could be
obtained due to a low VL or variant HIV subtype.
For 90 patients (61 adults, 29 children) the WHO failure
deﬁnition was fulﬁlled, and in 18 others ﬁrst and/or follow-up VL
were detectable but below 1000c/mL. Of those 90 failing
according to WHO deﬁnition 73 (81%) were found to harbor a
virus resistant against ≥2 drugs of their current ﬁrst-line regimen
(at least “low-level resistance” according to Stanford db version
7.0). Assuming that all patients with VL<80c/mL had a non-
resistant virus, theWHOdeﬁnition of failure had a sensitivity and
speciﬁcity for the presence of a resistant virus of 81% and 99%,
respectively. Of the 18 participants with elevated VL, who did not
fulﬁll the WHO failure deﬁnition, 17 (94.4%) harbored resistant
viruses (Table 3). Lowering the cut-off to 80c/mL increased
sensitivity to 100% while the speciﬁcity remained at 99%. The
positive predictive value (PPV) for the presence of a resistant virus
was 81.1% (95% CI: 72.2–88.9) using the WHO deﬁnition, and
83.3% (95% CI: 75.6–91.1) for a cut-off ≥80c/mL.
The strict application of the WHO recommended cut-off of
1000c/mL at ﬁrst and follow-up VL for deﬁnition of failure
would thus have missed 13/74 (17.6%) adults and 4/34 (11.8%)
children with therapy-threatening viral resistances. Having a VL
80 to 999c/mL at ﬁrst and/or follow-up VL had a negative
predictive value for a resistant virus of 5.6% (95% CI:
0%–16.7%). The 18 patients with VL 80 to 999c/mL presented
with a median VL of 360c/mL (IQR: 266–738).
3.4. Detection of RT inhibitor mutations
Among adults, no major mutations for NNRTI and NRTI were
present in 12.2% (9/74) and 13.5% (10/74) of all patients,
respectively. Similarly, 7 (20.6%) and 8 (23.5%) children were
found to harbor no major NNRTI- and NRTI-speciﬁc mutations,
respectively. All 3 children on a lopinavir-based ﬁrst-line therapy
carried viruses that had no major PI mutations. Figures 1 and 2 of
the Supplemental Digital Content, http://links.lww.com/MD/B62
(SDG) of this article display the frequencies of major NRTI- and
NNRTI-resistance mutations among the 74 adult and 34 pediatric
patients with successful HIV genotyping, who had presented with
ﬁrst- and second-VL above the plasma threshold of 80c/mL. The
SDG Table 1, http://links.lww.com/MD/B62 displays NRTI
resistances stratiﬁed by the ﬁrst-line NRTI backbone.4. Discussion and conclusionsThis prospective study conducted in 10 rural health facilities in
Lesotho assessed the WHO deﬁnition of virologic ART failure by6absence ofHIV drug resistance. One out of 5 patients fulﬁlling the
WHO failure deﬁnition carried a virus with no relevant resistance
against the current ﬁrst-line regimen, indicating a persisting
adherence issue. On the other hand, applying the strict WHO
threshold of 1000 copies in 2 consecutive VLs resulted in a
very signiﬁcant misclassiﬁcation of patients indeed harboring
resistant viruses with VLs between 80 and 999c/mL. In 17 of the
18 patients with sustained VL of 80 to 999c/mL resistant virus
was detected. More and more HIV programs in Sub Saharan
Africa nowadays use modern VL platforms that have detection
limits at below 1000copies/mL. This fact implies that also in
resource-limited settings the threshold for failure should be
lowered to, for example, “100c/mL at 2 consecutive VLs”. This
would enable an earlier detection of therapy failure and may thus
help to conserve, particularly in resource-limited settings, the
effectiveness of individual precious drugs in failing regimens.
The discrepancy between the current WHO failure threshold
and the detection of relevant genotypic resistance in this study
creates the situation that in resource-limited settings the switching
of patients strictly according to WHO guidelines may prevent a
considerable number of patients from receiving the needed
second-line therapy, whereas others, who would not require
second-line therapy at this point in time would be switched
unnecessarily. Both, delayed switch as well as nonindicated
switch to second-line, are of great clinical and public health
relevance. Patients, retained on a ﬁrst-line regimen without full
viral suppression, are at risk of acquiring further resistance
mutations[3,4] and may spread resistant HIV. Moreover, delayed
switching is associated with poorer response to second-line
therapy.[13,14]
In contrast, switching those patients to second-line, who
present with no mutations against their ﬁrst-line NRTI backbone
has been linked to poor outcome in observational studies[15] and
trials in resource-limited settings indicating unsolved adherence
problems after switch to second-line.[16,17] In addition, the switch
to a second-line regimen typically comes with a higher pill-burden
and tends to cause more side effects. Moreover, as currently
second-line regimens are still about 3 times more expensive than
the ﬁrst-line, every avoidable switch has also considerable
economic implications for resource-limited settings.[18]
Despite intensiﬁed adherence support after a ﬁrst unsuppressed
VL 13% of the adults and 31% of all children fulﬁlling theWHO
failure deﬁnition did not present any evidence for major viral
resistance against the current ﬁrst-line regimen (Table 3). This is
consistent with related studies from similar settings, which
showed that probably 10% to 20% of patients with sustained
virologic failure are switched to second-line therapy without
sufﬁcient virological evidence for resistance.[19–22] These studies
support the probably unique value of genotypic resistance testing
for resource-limited settings to discriminate true resistance-based [9] Ministry of Health of Lesotho. National guidelines on the use of
Labhardt et al. Medicine (2016) 95:28 www.md-journal.comfailures and VL elevations due to nonadherence.[23] Modeling
studies have already suggested that genotype-guided switching to
second-line (i.e., switch only undertaken when resistance is
detected), would be cost-effective.[24,25] To our knowledge,
however, there are currently no trials assessing the cost-
effectiveness of resistance testing in resource-limited settings.
A limitation of this study is the relatively low number of
patients with unsuppressed VL at ﬁrst measurement yielding only
a relatively small sample size of the cohort followed-up for second
VL. Of note, other reports from similar settings have reported
signiﬁcantly higher rates of unsuppressed VL.[26] Another
limitation is that patients included in the study had a median
time on ﬁrst-line ART of more than 4 years. Because patients did
not receive any VL monitoring prior to the study, the actual
duration of the period of failing therapy before ﬁrst measurement
is unknown. This could have favored a steady accumulation of
resistance mutations and might, in part, explain the rather
low resuppression rates in this study as compared to other
studies.[27]
In conclusion, our study provides evidence that the WHO-
recommended VL threshold of 1000c/mL is likely to miss a
substantial part of patients on ﬁrst-line ART with persisting virus
replication below 1000c/mL who carry drug-resistance muta-
tions. Lowering the VL cut-off to as low as 80c/mL did not lower
the PPV for the detection of therapy-relevant resistancemutations
in our study population. For programs using VL platforms with
detection limits below 1000c/mL, and if conﬁrmed by additional
studies, a revision of the current WHO threshold deﬁnition
for virologic failure in resource-limited settings should be
considered.
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